Details:
LNA043 is a ANGPTL3 agonist that targets damaged cartilage and modulates several pathways involved in cartilage regeneration. LNA043 resulted in regeneration of damaged cartilage in patients with femoral articular cartilage lesions in a proof of concept study.
Lead Product(s): LNA043,Canakinumab
Therapeutic Area: Musculoskeletal Product Name: LNA043
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021